Adicet Bio, Inc.
200 Constitution Drive
About Adicet Bio, Inc.
Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors. Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and then generating T Cell Receptor-like monoclonal antibodies (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs are being used to arm T cells or as T cell engagers in solid tumors. In August 2016, Adicet entered into a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology.
For more information, please visit our website at http://www.adicetbio.com.
20 articles with Adicet Bio, Inc.
Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced the appointment of Nick Harvey as Chief Financial Officer.
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer of Adicet Bio, will present at the Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020 at 8:40 AM ET. A live audio webcast of the presentation can be accessed on the Investors section of Ad
Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the completion of its previously announced merger with resTORbio, Inc. (previously trading on Nasdaq under the symbol “TORC”)
Adicet Bio, Inc., a privately-held biopharmaceutical company, announced that it has received a $10 million milestone payment from Regeneron associated with ADI-002 meeting key preclinical development goals, in accordance with the terms of its strategic collaboration with Regeneron.
The deal is expected to close in the second half of 2020. Once finalized, the combined company will run under the name Adicet Bio and is expected to trade on the Nasdaq Global Market under a new ticker symbol, which hasn’t been announced yet.
resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology
Adicet’s lead asset ADI-001 is an allogeneic gamma delta T cell therapy expressing a chimeric antigen receptor targeting CD20 for treatment of non-Hodgkin’s lymphoma
Adicet Bio, Inc., a biopharmaceutical company focused on the development of allogeneic cell therapies for cancer using innovative gamma delta T cells, announced today that the company will present at the 38th Annual J.P. Morgan Healthcare Conference.
As part of the Series B financing, aMoon and JJDC will be joining Adicet's Board of Directors.
Adicet Bio, Inc., a biopharmaceutical company focused on the development of allogeneic cell therapies for cancer using innovative gamma delta T cells, announced today the appointment of Francesco Galimi, M.D., Ph.D., as Senior Vice President and Chief Medical Officer.
Adicet Bio, Inc. announced that the Board of Directors has appointed Anil Singhal, Ph.D., MBA, President and Chief Executive Officer, effective May 6, 2019.
Adicet Bio, Inc. announced today that the company will present at the 37th Annual J.P. Morgan Healthcare Conference.
Dr. Abbot brings extensive industry experience in the research, early product development and clinical translation of cell-based therapies.
Adicet Bio, Inc. announced that it has appointed Elizabeth "E.J." Read, M.D. as its Chief Technology Officer. Dr. Read brings extensive industry experience in the successful development of cell-based biological therapies.
Adicet Bio Announces the Transition of Founder, President and Chief Executive Officer Dr. Aya Jakobovits
Adicet Bio, Inc. ("Adicet"), a biopharmaceutical company focused on the development of next-generation cell immunotherapies, announced today that Aya Jakobovits, Ph.D., Founder of Adicet Bio, has retired from her position as President and Chief Executive Officer.
BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014.
After Bagging $51 Million in Early 2016, Bay Area's Adicet Bio Inks a Five-Year R&D Deal with Regeneron
The Bay Area's Secretive Adicet Bio Raises $51 Million and Buys Israel-based Applied Immune Technologies